| 刘立杰,高立明,张 双.尼妥珠单抗联合同步放化疗治疗Her-2阴性局部晚期胃癌疗效观察[J].肿瘤学杂志,2016,22(9):713-717. |
| 尼妥珠单抗联合同步放化疗治疗Her-2阴性局部晚期胃癌疗效观察 |
| Efficacy of Nimotuzumab in Combination with Concurrent Chemoradiotherapy for Treatment of Her-2 Negative Local Advanced Gastric Cancer |
| 投稿时间：2015-10-23 |
| DOI：10.11735/j.issn.1671-170X.2016.09.B005 |
|
 |
| 中文关键词: 胃肿瘤 尼妥珠单抗 同步放化疗 卡培他滨 |
| 英文关键词:gastric neoplasms nimotuzumab concurrent chemoradiotheray capecitabine |
| 基金项目:秦皇岛市科技研究与发展计划（2012023A081） |
|
| 摘要点击次数: 1418 |
| 全文下载次数: 611 |
| 中文摘要: |
| 摘 要：［目的］ 研究Her-2阴性局部晚期胃癌患者应用尼妥珠单抗联合单药卡培他滨方案同步放疗的疗效及不良反应。［方法］ 选取58例Her-2阴性局部晚期胃癌患者，其中25例为尼妥珠单抗组，应用尼妥珠单抗（100mg/次，放疗第1、8、15、22、29d，放疗前静脉滴注）联合单药卡培他滨（625～825mg/m2，口服，每日2次，共5周）化疗，同步行三维适形放疗(45～50Gy/25次)；33例为放化疗组，单纯应用单药卡培他滨方案同步三维适形放疗，放化疗剂量同尼妥珠单抗组。对患者进行随访，分析其疗效及不良反应。［结果］ 尼妥珠单抗组与放化疗组部分缓解率分别为68.00%和39.39%(P<0.05)。尼妥珠单抗组患者梗阻、疼痛缓解率分别为77.78%(14/18)、85.00%(17/20)。放化疗组患者梗阻、疼痛缓解率分别为42.86%(12/28)、56.00%(14/25)。二组间差异均有统计学意义(P<0.05)。尼妥珠单抗组发生血液学不良反应为80.00%，胃肠道不良反应为96.00%，手足综合征为68.00%；放化疗组则分别为81.82%、93.94%、60.61%，二组间差异均无统计学意义（P>0.05）。［结论］ 尼妥珠单抗联合单药卡培他滨方案同步放疗治疗Her-2阴性局部晚期胃癌患者，可以提高局部缓解率，提高生活质量，并未增加不良反应。 |
| 英文摘要: |
| Abstract：［Objective］ To evaluate the efficacy and adverse effect of nimotuzumab in combination with concurrent chemoradiotherapy for treatment of Her-2 negative local advanced gastric cancer. ［Methods］ Fifty-eight Her-2 negative local advanced gastric cancer patients，whose tumors were inoperable or who did not intend to be operated，were enrolled in the study．Patients were divided into nimotuzumab group(n=25) and control group(n=33). Both groups were given capecitabine（625～825mg/m2，p.o，b.i.d，for 5 weeks），concurrent with three dimensional conformal radiation therapy with a dose of 40~50Gy/25f，5 times weekly. Patients in nimotuzumab group additionally received nimotuzumab 100mg i.v. weekly for 5 weeks from d1 of concurrent chemoradiotherapy. Efficacy and adverse effect in two groups were evaluated. ［Results］ Partial remission rate was 68.00% in nimotuzumab group and 39.39% in concurrent chemoradiotherapy group (P<0.05). Remission rate of dysphagia/obstruction and pain were 77.78% (14/18) and 85.00% (17/20) in nimotuzumab group；42.86% (12/28) and 56.00%(14/25) in control group (P<0.05). The rates of hematologic toxicities，gastrointestinal adverse reactions and hand-foot syndrome were 80.00%，96.00% and 68.00% in nimotuzumab group，and 81.82%，93.94% and 60.61% in control group（P>0.05）.［Conclusion］ Nimotuzumab in combination with concurrent chemoradiotherapy is effective in treatment of Her-2 negative local advanced gastric cancer，without increasing adverse reactions. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |